Head skin infection by Candida auris: A case report

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2025-03-18 DOI:10.1016/j.mycmed.2025.101544

Jueting Tang, Kaiying Yang, Zhixin Cui, Yanhong Guan, Zelun Li

{"title":"Head skin infection by Candida auris: A case report","authors":"Jueting Tang, Kaiying Yang, Zhixin Cui, Yanhong Guan, Zelun Li","doi":"10.1016/j.mycmed.2025.101544","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>Candida auris</em> is a recently discovered yeast species first found in 2009 in the ear discharge of a patient in Japan. Known for its high mortality rate, strong transmissibility, ability to cause hospital outbreaks, and resistance to multiple drugs, it has earned the nickname \"superbug\". Currently, there are five main clades of <em>Candida auris</em> identified, including the South Asian, East Asian, South African, South American, and a newly discovered fifth clade in Iran. Infection cases have been documented in over 40 countries across six continents, drawing global attention. In 2022, the World Health Organization (WHO) designated <em>Candida auris</em> as a top priority pathogen in their inaugural list of fungal threats to health. The lack of standardized and effective treatment protocols and prevention strategies has resulted in numerous treatment and control failures. To delve deeper into the clinical management strategies and hospital infection control measures for Candida auris, we conducted a retrospective analysis of a <em>Candida auris</em> infection case and briefly reviewed relevant literature.</div></div><div><h3>Case presentation</h3><div>A 54-year-old male patient with a complex medical history developed a <em>Candida auris</em> infection, presenting with ulcerative scalp lesions. The medical team implemented local wound care measures, including iodophor disinfection and infrared therapy, and strictly adhered to the hospital's infection control protocols, successfully controlling the <em>Candida auris</em> infection without any nosocomial transmission.</div></div><div><h3>Conclusion</h3><div>This case study highlights the importance of individualized treatment and tailored infection control measures implemented through interdisciplinary teamwork. The successful management underscores the potential for containing the spread of Candida auris, offering valuable insights for future strategies against this emerging multidrug-resistant pathogen. However, the complex challenges in diagnosing, treating, and controlling <em>Candida auris</em> infections emphasize the imperative need to enhance research and establish standardized protocols.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"35 2","pages":"Article 101544"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523325000137","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Candida auris is a recently discovered yeast species first found in 2009 in the ear discharge of a patient in Japan. Known for its high mortality rate, strong transmissibility, ability to cause hospital outbreaks, and resistance to multiple drugs, it has earned the nickname "superbug". Currently, there are five main clades of Candida auris identified, including the South Asian, East Asian, South African, South American, and a newly discovered fifth clade in Iran. Infection cases have been documented in over 40 countries across six continents, drawing global attention. In 2022, the World Health Organization (WHO) designated Candida auris as a top priority pathogen in their inaugural list of fungal threats to health. The lack of standardized and effective treatment protocols and prevention strategies has resulted in numerous treatment and control failures. To delve deeper into the clinical management strategies and hospital infection control measures for Candida auris, we conducted a retrospective analysis of a Candida auris infection case and briefly reviewed relevant literature.

Case presentation

A 54-year-old male patient with a complex medical history developed a Candida auris infection, presenting with ulcerative scalp lesions. The medical team implemented local wound care measures, including iodophor disinfection and infrared therapy, and strictly adhered to the hospital's infection control protocols, successfully controlling the Candida auris infection without any nosocomial transmission.

Conclusion

This case study highlights the importance of individualized treatment and tailored infection control measures implemented through interdisciplinary teamwork. The successful management underscores the potential for containing the spread of Candida auris, offering valuable insights for future strategies against this emerging multidrug-resistant pathogen. However, the complex challenges in diagnosing, treating, and controlling Candida auris infections emphasize the imperative need to enhance research and establish standardized protocols.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.